Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 1,396 Shares of Stock

Key Points

• Pushkal Garg, the Executive Vice President of Alnylam Pharmaceuticals, sold 1,396 shares at an average price of $453.27, decreasing his stake by 6.05% to 21,676 shares valued at approximately $9.83 million.
• Alnylam Pharmaceuticals reported a quarterly earnings per share of $0.32, significantly beating estimates of ($0.54) and showing a 17.3% year-over-year revenue growth to $773.69 million.
• Analysts have raised price targets for Alnylam stock, with Oppenheimer setting a new target of $490.00 and Barclays increasing theirs to $460.00, indicating a consensus rating of "Moderate Buy."

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) EVP Pushkal Garg sold 1,396 shares of the company's stock in a transaction that occurred on Monday, August 18th. The stock was sold at an average price of $453.27, for a total value of $632,764.92. Following the sale, the executive vice president owned 21,676 shares in the company, valued at approximately $9,825,080.52. This represents a 6.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, August 19th, Pushkal Garg sold 1,455 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $458.41, for a total value of $666,986.55.

Alnylam Pharmaceuticals Stock Performance

ALNY traded up $1.41 during trading hours on Tuesday, reaching $458.28. The company's stock had a trading volume of 1,321,747 shares, compared to its average volume of 957,852. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $462.88. The company's 50-day moving average is $348.15 and its 200-day moving average is $291.81. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The firm has a market cap of $60.07 billion, a PE ratio of -185.54 and a beta of 0.25.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $773,689 billion for the quarter, compared to analysts' expectations of $633.54 million. During the same quarter in the prior year, the business earned ($0.13) EPS. The firm's revenue for the quarter was up 17.3% on a year-over-year basis. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Large investors have recently bought and sold shares of the company. Atlantic Union Bankshares Corp bought a new position in Alnylam Pharmaceuticals in the second quarter valued at about $30,000. SVB Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals during the first quarter worth about $27,000. Whipplewood Advisors LLC raised its position in shares of Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 176.9% during the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC bought a new position in shares of Alnylam Pharmaceuticals during the second quarter worth about $37,000. 92.97% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several analysts have recently issued reports on the company. Oppenheimer raised Alnylam Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $490.00 target price on the stock in a report on Monday, August 4th. Barclays increased their target price on Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an "overweight" rating in a report on Friday, August 1st. Wall Street Zen raised Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Citigroup increased their target price on Alnylam Pharmaceuticals from $364.00 to $404.00 and gave the stock a "buy" rating in a report on Friday, July 11th. Finally, Wells Fargo & Company upped their price objective on Alnylam Pharmaceuticals from $333.00 to $395.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $405.33.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.